The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Everest Medicines unveils breakthroughs in AI+mRNA platform, reinforces global leadership in next-gen mRNA innovation: Hong Kong Monday, July 7, 2025, 10:00 Hrs [IST] Everest Medi ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The author says the action creates mistrust of the committee’s vaccine recommendations and further increases patients’ and ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...